Successful clinical study for an innovative dengue vaccine, supervised by UNIL professor – News – CIVIS – Europe’s Civic University Alliance [Skip to content](#main) ![](https://civis.eu/build/assets/circle-07-COrlhHVd.svg) ![](https://civis.eu/build/assets/circle-03-DvaxLIQk.svg) ![](https://civis.eu/build/assets/circle-09-B3BMjMVU.svg) [ ![CIVIS – Europe’s Civic University Alliance](https://civis.eu/build/assets/civis-CCpvK1nT.svg)](https://civis.eu/en) - [ Discover ](https://civis.eu/en/discover-civis-alliance) - [ What is CIVIS? ](https://civis.eu/en/discover-civis-alliance/what-is-civis) - [ Our work ](https://civis.eu/en/discover-civis-alliance/our-work) - [ Mission, Vision & Values ](https://civis.eu/en/discover-civis-alliance/mission-vision-values) - [ Governance & Management ](https://civis.eu/en/discover-civis-alliance/governance-andamp-management) - [ Who's Who ](https://civis.eu/en/discover-civis-alliance/who-is-who) - [ CIVIS Association ](https://civis.eu/en/discover-civis-alliance/civis-association) [Open Labs & Civic engagement ](https://civis.eu/en/discover-civis-alliance/our-work/open-labs-civic-engagement) - [ Learn ](https://civis.eu/en/learn) - [ Blended Intensive Programmes ](https://civis.eu/en/learn/blended-intensive-programmes) - [ Flexible Learning ](https://civis.eu/en/learn/build-your-learning-path-flexible-offer) - [ Master’s Programmes ](https://civis.eu/en/learn/find-your-master-s-programme) - [ Staff weeks & Job Shadowing ](https://civis.eu/en/learn/keep-on-learning-with-staff-weeks-andamp-job-shadowing) - [ Study abroad ](https://civis.eu/en/learn/study-abroad-and-connect-with-civis-universities) [Discover the projects led by our students in 2025-2026 ](https://civis.eu/en/discover-civis-alliance/our-work/student-led-projects/discover-the-projects-led-by-our-students-in-2025-2026) [CIVIS Museum University Forum ](https://civis.eu/en/discover-civis-alliance/our-work/CIVIS-Museum-University-Forum) - [ Teach ](https://civis.eu/en/teach) - [ Calls for Projects ](https://civis.eu/en/teach/civis-calls) - [ Innovate your Teaching ](https://civis.eu/en/teach/innovate-your-teaching) - [ Resources for Educators ](https://civis.eu/en/teach/resources-for-educators) [CIVIS BIPs: strong impact and high satisfaction, new report finds ](https://civis.eu/en/the-civis-newsroom/civis-bips-strong-impact-and-high-satisfaction-new-report-finds) [When art speaks louder than headlines: CIVIS Open Lab participants reclaim the meaning of home ](https://civis.eu/en/the-civis-newsroom/when-art-speaks-louder-than-headlines-civis-open-lab-reclaims-the-meaning-of-home) - [ Research ](https://civis.eu/en/providing-the-tools-for-innovative-research) - [ Research Collaboration ](https://civis.eu/en/providing-the-tools-for-innovative-research/research-collaboration) - [ Careers, Networks & Mobilities ](https://civis.eu/en/providing-the-tools-for-innovative-research/research-careers-networks-and-projects) - [ Resources for Researchers ](https://civis.eu/en/providing-the-tools-for-innovative-research/resources-for-researchers) [I am an academic/ researcher ](https://civis.eu/en/i-am-an-academic-researcher) [Facing Common Challenges, Shaping Joint Solutions for Africa and Europe ](https://civis.eu/en/the-civis-newsroom/facing-common-challenges-shaping-joint-solutions-for-africa-and-europe) - [ Connect ](https://civis.eu/en/connect) - [ Newsletters ](https://civis.eu/en/connect/newsletters) - [ CIVIS Days ](https://civis.eu/en/connect/civis-days) - [ Civil Society ](https://civis.eu/en/discover-civis-alliance/our-work/open-labs-civic-engagement) - [ Contact us ](https://civis.eu/en/contact) - [ Press Corner & Branding ](https://civis.eu/en/connect/press-corner-branding-toolkit) [Who’s Who ](https://civis.eu/en/discover-civis-alliance/who-is-who) [Fake It Till You News It: Challenges and Solutions in Modern Media Student Innovation Forum ](https://civis.eu/en/discover-civis-alliance/our-work/student-led-projects/discover-the-projects-led-by-our-students-in-2025-2026/civis-creathon-contest) [ Our stories ](https://civis.eu/en/the-civis-newsroom) en - [ de ](https://civis.eu/de/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ fr ](https://civis.eu/fr/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ el ](https://civis.eu/el/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ it ](https://civis.eu/it/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ es ](https://civis.eu/es/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ sv ](https://civis.eu/sv/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ ro ](https://civis.eu/ro/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) Menu - [Discover](https://civis.eu/en/discover-civis-alliance) [ Toggle submenu ](#primary-nav-sm-collapse-29) - [ What is CIVIS? ](https://civis.eu/en/discover-civis-alliance/what-is-civis) - [ Our work ](https://civis.eu/en/discover-civis-alliance/our-work) - [ Mission, Vision & Values ](https://civis.eu/en/discover-civis-alliance/mission-vision-values) - [ Governance & Management ](https://civis.eu/en/discover-civis-alliance/governance-andamp-management) - [ Who's Who ](https://civis.eu/en/discover-civis-alliance/who-is-who) - [ CIVIS Association ](https://civis.eu/en/discover-civis-alliance/civis-association) - [Learn](https://civis.eu/en/learn) [ Toggle submenu ](#primary-nav-sm-collapse-30) - [ Blended Intensive Programmes ](https://civis.eu/en/learn/blended-intensive-programmes) - [ Flexible Learning ](https://civis.eu/en/learn/build-your-learning-path-flexible-offer) - [ Master’s Programmes ](https://civis.eu/en/learn/find-your-master-s-programme) - [ Staff weeks & Job Shadowing ](https://civis.eu/en/learn/keep-on-learning-with-staff-weeks-andamp-job-shadowing) - [ Study abroad ](https://civis.eu/en/learn/study-abroad-and-connect-with-civis-universities) - [Teach](https://civis.eu/en/teach) [ Toggle submenu ](#primary-nav-sm-collapse-31) - [ Calls for Projects ](https://civis.eu/en/teach/civis-calls) - [ Innovate your Teaching ](https://civis.eu/en/teach/innovate-your-teaching) - [ Resources for Educators ](https://civis.eu/en/teach/resources-for-educators) - [Research](https://civis.eu/en/providing-the-tools-for-innovative-research) [ Toggle submenu ](#primary-nav-sm-collapse-32) - [ Research Collaboration ](https://civis.eu/en/providing-the-tools-for-innovative-research/research-collaboration) - [ Careers, Networks & Mobilities ](https://civis.eu/en/providing-the-tools-for-innovative-research/research-careers-networks-and-projects) - [ Resources for Researchers ](https://civis.eu/en/providing-the-tools-for-innovative-research/resources-for-researchers) - [Connect](https://civis.eu/en/connect) [ Toggle submenu ](#primary-nav-sm-collapse-33) - [ Newsletters ](https://civis.eu/en/connect/newsletters) - [ CIVIS Days ](https://civis.eu/en/connect/civis-days) - [ Civil Society ](https://civis.eu/en/discover-civis-alliance/our-work/open-labs-civic-engagement) - [ Contact us ](https://civis.eu/en/contact) - [ Press Corner & Branding ](https://civis.eu/en/connect/press-corner-branding-toolkit) [ Our stories ](https://civis.eu/en/the-civis-newsroom) en - [ de ](https://civis.eu/de/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ fr ](https://civis.eu/fr/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ el ](https://civis.eu/el/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ it ](https://civis.eu/it/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ es ](https://civis.eu/es/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ sv ](https://civis.eu/sv/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) - [ ro ](https://civis.eu/ro/the-civis-newsroom/successful-clinical-study-for-an-innovative-dengue-vaccine-supervised-by-unil-s-professor) 1. [The CIVIS Newsroom ](https://civis.eu/en/the-civis-newsroom) 2. Successful clinical study for an innovative dengue vaccine, supervised by UNIL professor Successful clinical study for an innovative dengue vaccine, supervised by UNIL professor ========================================================================================== CIVIS Highlights 16 February 2024 A new type of vaccine that induces cellular immunity to combat dengue fever has been the subject of a clinical study conducted by [Unisanté](https://www.unisante.ch/fr). The results, supervised by a professor from CIVIS member University UNIL, have just been published in the journal "*The Lancet eBioMedicine*" and encourage further investigation. This approach is also promising for other diseases. ![](/storage/files/header-stm-2022_2.png) stock photo by Canva​​​​​ A global health priority ------------------------ Global warming and urbanisation are facilitating the spread of the tiger mosquito, responsible for dengue fever. The World Health Oorganisation (WHO) estimates that almost half the world's population now lives in high-risk areas. Cases of dengue fever have increased eightfold in 20 years, leading to one hospitalisation per minute and two deaths per hour. Having **an effective vaccine is therefore a priority for global health**. Two dengue vaccines are currently available in Europe, but they are unsatisfactory in terms of safety and efficacy. Their technology is based on the production of antibodies which, in certain cases, can increase the severity of the disease when infected by the natural virus. Unisanté has evaluated the safety and immune response of a potential dengue vaccine (*PepGNP Dengue*), designed using an innovative technology to induce cellular immunity without stimulating antibody production. New approach and nano-innovations --------------------------------- The tested vaccine, PepGNP-Dengue, was developed in the UK by Emergex Vaccines. It consists of a nanodose of synthetic fragments of the virus fused to gold nanoparticles. Another special feature is that it is administered under the skin using a micro-needle. The vaccine relies on T lymphocytes, which are responsible for cellular immunity, to eliminate cells infected by the virus and prevent it from replicating. Emergex Vaccines chose Unisanté to carry out the clinical study in order to assess the safety of this vaccine, which is being administered to humans for the first time, given the institution's accumulated experience in evaluating vaccine candidates against Ebola and malaria in particular. The aim of phase 1 was to determine whether the vaccine did not induce severe undesirable side-effects in non-diseased volunteers. A total of 26 participants aged between 18 and 45 were vaccinated in Lausanne in 2021, and were followed for six months until March 2022. The results of this clinical study, supervised by Blaise Genton, Honorary Professor at UNIL, and coordinated by Dr Alix Miauton, Research Fellow at Unisanté, were published in January 2024 in The Lancet eBioMedicine. Positive results without adverse effects ---------------------------------------- During the trial, no serious adverse events related to the vaccine occurred. Local side effects (such as pain at the injection site) were the most frequently reported. Immunological results indicate that PepGNP-Dengue can stimulate a specific cellular response against the dengue virus without producing antibodies. These findings encourage further investigation into this innovative vaccine candidate and hold promise for other diseases where cellular immunity is important. A potential COVID-19 vaccine based on the same technology has also been tested by Unisanté on 26 participants, with results currently being published. **Dig into the [original story](https://news.unil.ch/display/1706104853462), in French.** Related news ------------ - [ ![](https://civis.eu/storage/files/unil-march-800x600.jpg?token=d8f751c5dd64924dd2e37edbb187d325)The Swiss ski mountaineering team, supported by UNIL's researchers for this year's Olympic Games CIVIS Highlights 3 March 2026 ](https://civis.eu/en/the-civis-newsroom/the-swiss-ski-mountaineering-team-supported-by-unil-s-researchers-for-this-year-s-olympic-games) - [ ![](https://civis.eu/storage/files/post-it-risks-800x600.jpg?token=3f32ba7f3ab0220e88eeac41defdd8bf)Innovative micro-credential for professionals on AI for the workplace launched by CIVIS Learn 10 February 2026 ](https://civis.eu/en/the-civis-newsroom/innovative-micro-credential-professionals-ai-workplace-civis) - [ ![](https://civis.eu/storage/files/img-4583-800x600.jpg?token=9b1616d14128b09af2bc51cc05d57631)UNIL empowers master’s students to co-create research with partners in the field abroad CIVIS Highlights 17 October 2025 ](https://civis.eu/en/the-civis-newsroom/unil-empowers-master-s-students-to-co-create-research-with-partners-in-the-field-abroad) [Discover all our stories](https://civis.eu/en/the-civis-newsroom) [ Mission Europe pour la Recherche: towards a one-stop shop for European research funding ](< https://civis.eu/en/the-civis-newsroom/towards-a-one-stop-shop-to-apply-for-european-funding-launch-of-the-mission-europe-pour-la-recherche >) [ Sustainable renovation of the Lubumbashi University Clinics proposed by ULB-UNILU students ](< https://civis.eu/en/the-civis-newsroom/ulb-unilu-student-microproject-a-sustainable-renovation-of-the-lubumbashi-university-clinics >) ![CIVIS – Europe’s Civic University Alliance](https://civis.eu/build/assets/civis-CCpvK1nT.svg) ------------------------------------------------------------------------------------------------- Europe’s Civic University Alliance ![Co-funded by the European Union](https://civis.eu/build/assets/co-funded-by-the-european-union-DSKLW1us.png)Views and opinions expressed do not necessarily reflect those of the European Union or the European Education and Culture Executive Agency (EACEA). Neither can be held responsible for them. ### People - [ Students ](https://civis.eu/en/i-am-a-student) - [ Academics & researchers ](https://civis.eu/en/i-am-an-academic-researcher) - [ Administrators ](https://civis.eu/en/i-am-an-administrator) - [ Civil society ](https://civis.eu/en/discover-civis-alliance/our-work/open-labs-civic-engagement) - [ Press corner & Branding ](https://civis.eu/en/connect/press-corner-branding-toolkit) ### Useful links - [ Resources ](https://civis.eu/en/resources) - [ CIVIS Agora ](https://civis.eu/en/civis-agora-the-operational-hub-of-the-civis-digital-campus) - [ European Universities initiative ](https://civis.eu/en/european-universities-initiative) - [ Past Events ](https://civis.eu/en/past-events) - [ Contact ](https://civis.eu/en/contact) [Newsletters](https://civis.eu/en/connect/newsletters) ### Social networks - [ ![](https://civis.eu/storage/files/instagram.svg) Instagram ](https://www.instagram.com/civis.eu/) - [ ![](https://civis.eu/storage/files/linkedin.svg) LinkedIn ](https://www.linkedin.com/company/civis-eu) - [ ![](https://civis.eu/storage/files/facebook.svg) Facebook ](https://www.facebook.com/CIVISEuropeanUniversity/) - [ ![](https://civis.eu/storage/files/youtube.svg) YouTube ](https://www.youtube.com/channel/UCdCm0FfreX81BuNH-znlRGQ) © 2026 – CIVIS – All rights reserved - [ Cookie Policy ](https://civis.eu/en/cookie-policy) - [ Privacy policy ](https://civis.eu/en/privacy-policy) Website by [Typi Design](https://typi.be) • Design by [Atelier Milky](https://ateliermilky.com) [ ](#top) Search